hVIVO Management

Management criteria checks 2/4

hVIVO's CEO is Mo Khan, appointed in Feb 2022, has a tenure of 2.17 years. total yearly compensation is £591.54K, comprised of 44% salary and 56% bonuses, including company stock and options. directly owns 0.077% of the company’s shares, worth €172.86K. The average tenure of the management team and the board of directors is 2.2 years and 3 years respectively.

Key information

Mo Khan

Chief executive officer

UK£591.5k

Total compensation

CEO salary percentage	44.0%
CEO tenure	2.2yrs
CEO ownership	0.08%
Management average tenure	2.2yrs
Board average tenure	3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mo Khan's remuneration changed compared to hVIVO's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	UK£16m
Sep 30 2023	n/a	n/a	UK£9m
Jun 30 2023	n/a	n/a	UK£3m
Mar 31 2023	n/a	n/a	UK£1m
Dec 31 2022	UK£592k	UK£260k	-UK£776k

Compensation vs Market: Mo's total compensation ($USD739.29K) is about average for companies of similar size in the Irish market ($USD589.42K).

Compensation vs Earnings: Insufficient data to compare Mo's compensation with company performance.

CEO

Mo Khan (54 yo)

2.2yrs

Tenure

UK£591,540

Compensation

Dr. Yamin Mohammed Khan, also known as Mo, serves as Chief Executive Officer at hVIVO plc (formerly known as Open Orphan Plc) since February 24, 2022 and also serves as its Director since 2022. He was Inde...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yamin Khan	CEO & Director	2.2yrs	UK£591.54k	0.077% £ 172.9k
Stephen Pinkerton	CFO & Executive Director	1.5yrs	UK£185.33k	no data
Andrew Catchpole	Chief Scientific Officer	no data	no data	no data
Maurice Treacy	Chief Commercial Officer	4.8yrs	no data	no data
Teja Marathe-Sarvadikar	Head of QA	2.3yrs	no data	no data

2.2yrs

Average Tenure

Experienced Management: HVO's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yamin Khan	CEO & Director	2.5yrs	UK£591.54k	0.077% £ 172.9k
Stephen Pinkerton	CFO & Executive Director	1.5yrs	UK£185.33k	no data
Brendan Buckley	Member of Advisory Board & Non-Executive Director	no data	UK£45.00k	1.18% £ 2.7m
Cathal Friel	Chairman of the Board	4.3yrs	UK£231.32k	2.19% £ 4.9m
Martin Gouldstone	Independent Non-Executive Director	1.8yrs	UK£25.00k	no data
Elaine Sullivan	Independent Non-Executive Director	3.4yrs	UK£47.00k	no data
John Oxford	Chair of Advisory Board	4.2yrs	no data	no data

3.0yrs

Average Tenure

59.5yo

Average Age

Experienced Board: HVO's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.

hVIVO Management

Management criteria checks 2/4

Key information

Recent management updates

hVIVO plc, Annual General Meeting, May 13, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

hVIVO plc, Annual General Meeting, May 13, 2024

Full year 2023 earnings released: EPS: UK£0.024 (vs UK£0.001 loss in FY 2022)

hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

New minor risk - Share price stability

hVIVO plc Signs £6.3 Million Human Challenge Study Model

hVIVO plc Increases Revenue Guidance for 2023

hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023

hVIVO plc to Develop Human Metapneumovirus Challenge Model

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

hVIVO plc Provides Earnings Guidance for the Full Year 2022

Less than half of directors are independent

Forecast breakeven date pushed back to 2023

Less than half of directors are independent

hVIVO plc Announces Publication of Imutex Phase I Data

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Less than half of directors are independent

Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-V

Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022

Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022

Less than half of directors are independent

Less than half of directors are independent

Open Orphan plc Announces Characterisation Study Results in Nature Medicine

Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive Officer

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Forecast to breakeven in 2022

Less than half of directors are independent

First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)

Less than half of directors are independent

Forecast to breakeven in 2022

Full year 2020 earnings released: UK£0.018 loss per share (vs UK£0.034 loss in FY 2019)

Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge Study

New 90-day high: €0.34

Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna Biosciences

Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021

Open Orphan plc Announces Board Changes, Effective on December 31, 2020

Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVO

Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge Study

Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age